The FDA has expanded the use of Regeneron’s antibody cocktail, REGEN-COV, updating its emergency use authorisation (EUA) to include those at high risk of developing severe COVID-19 who have been exposed to the virus.
The therapy – a combination of monoclonal antibodies casirivimab and imdevimab – is now the only COVID-19 antibody therapy available in the US for both treatment and post-exposure prophylaxis, says the company.
REGEN-COV is not the only antibody drug on the market. Lilly’s bamlanivimab/etesevimab combo and GSK/Vir’s sotrovimab were approved earlier this year. However, recent trial data may mean Regeneron is pulling ahead in the COVID-19 antibody drug race.